Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Any drug that works has a target

Any drug that works has a target Targ Oncol (2006) 1:179–180 DOI 10.1007/s11523-006-0028-z EDITORIAL James O. Armitage Received: 28 July 2006 /Accepted: 24 August 2006 / Published online: 23 September 2006 Springer-Verlag 2006 Paul Ehrlich was one of the innovative scientists of the later kinase inhibitors, protease inhibitors, histone deacetylase nineteenth and early twentieth century. He provided much inhibitors, etc. However, any physician who uses the of the basis for chemotherapy that is used today in antibody alemtuzumab or the protease inhibitor bortezomib infectious disease and cancer. Ehrlich coined the term knows that these drugs are not without toxicity. “magic bullet” to describe a chemical treatment that would Although active as single agents, it is likely that the most kill the disease but leave the patient unharmed [1]. Today, effective use of many targeted therapies will be in we continue to search for magic bullets against cancer. We combination with preexisting agents. For example, addition are fortunate to have many anticancer drugs that work and of the antibody rituximab to CHOP chemotherapy has can now use them to cure a variety of cancers. Unfortu- strikingly improved the cure rate for patients with diffuse nately, all have side effects, and sometimes the treatment large B-cell lymphoma [2, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

Any drug that works has a target

Armitage, James
Targeted Oncology , Volume 1 (4) – Sep 23, 2006
Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/any-drug-that-works-has-a-target-u5JasQk6My

References (12)

Publisher
Springer Journals
Copyright
Copyright © 2006 by Springer-Verlag
Subject
Medicine & Public Health; Biomedicine general; Oncology
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-006-0028-z
Publisher site
See Article on Publisher Site

Abstract

Targ Oncol (2006) 1:179–180 DOI 10.1007/s11523-006-0028-z EDITORIAL James O. Armitage Received: 28 July 2006 /Accepted: 24 August 2006 / Published online: 23 September 2006 Springer-Verlag 2006 Paul Ehrlich was one of the innovative scientists of the later kinase inhibitors, protease inhibitors, histone deacetylase nineteenth and early twentieth century. He provided much inhibitors, etc. However, any physician who uses the of the basis for chemotherapy that is used today in antibody alemtuzumab or the protease inhibitor bortezomib infectious disease and cancer. Ehrlich coined the term knows that these drugs are not without toxicity. “magic bullet” to describe a chemical treatment that would Although active as single agents, it is likely that the most kill the disease but leave the patient unharmed [1]. Today, effective use of many targeted therapies will be in we continue to search for magic bullets against cancer. We combination with preexisting agents. For example, addition are fortunate to have many anticancer drugs that work and of the antibody rituximab to CHOP chemotherapy has can now use them to cure a variety of cancers. Unfortu- strikingly improved the cure rate for patients with diffuse nately, all have side effects, and sometimes the treatment large B-cell lymphoma [2,

Journal

Targeted Oncology – Springer Journals

Published: Sep 23, 2006

There are no references for this article.